Why Is AIM Stock Rising Today? AIM ImmunoTech Climbs After Phase 2 DURIPANC Trial Dosing Completion

AIM ImmunoTech (AIM) shares rose 10.33% in intraday trading on Monday after the company announced the ahead-of-schedule completion of dosing in its Phase 2 DURIPANC trial for pancreatic cancer. The company also highlighted encouraging exploratory survival data from a Named Patient Program.

What Did AIM ImmunoTech Announce?

The company said the final subject in the Phase 2 DURIPANC trial received the last dose ahead of the planned schedule.

The trial is evaluating Ampligen (rintatolimod) in combination with standard-of-care chemotherapy for patients with late-stage pancreatic cancer. In the same press release, the company reported exploratory data from a Named Patient Program showing a median overall survival of 34.8 months in a patient subset with a specific biomarker, compared to 12.5 months for historical controls. The company said it is using this biomarker data to inform the design of future registrational trials.

AIM shares gained 10.33% during the session. Trading volume was below the stock's 20-day average, suggesting that broader participation has not yet fully formed behind the intraday move.

Why Does The Update Matter?

Pancreatic cancer remains one of the most difficult-to-treat cancers, with limited options and historically poor survival rates. A clinical signal pointing to a meaningful survival benefit draws attention in a disease area where progress has been slow.

The ahead-of-schedule dosing completion removes a timeline uncertainty for the DURIPANC program and shows the company can execute on its clinical plan. The exploratory survival data, while preliminary, suggests a potential biomarker-driven patient-selection strategy that could improve the odds of success in later-stage studies.

That said, the survival figures come from a small, exploratory patient group rather than from the randomized DURIPANC trial itself. Topline data from the main Phase 2 study has not yet been reported.

What Should Investors Watch Next?

The primary event ahead is the topline data readout from the DURIPANC trial, which will show whether the Ampligen-chemotherapy combination met its efficacy endpoints. Any update on the timing or design of a registrational Phase 3 program would be a material signal for the investment case.

For a small-cap biotech with a stock price near $1.43, clinical news can drive sharp moves in both directions. The exploratory data comes from a specific biomarker subset and may not replicate in the broader DURIPANC patient population.